Dentsply (XRAY) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
07 Nov 2024

Dentsply International (XRAY) reported $951 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 0.4%. EPS of $0.50 for the same period compares to $0.49 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $942.6 million, representing a surprise of +0.89%. The company delivered an EPS surprise of +4.17%, with the consensus EPS estimate being $0.48.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Dentsply performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Organic sales growth: 1.3% compared to the 0.9% average estimate based on six analysts.
  • Revenues- United States: $374 million versus $354.69 million estimated by three analysts on average.
  • Revenues- Rest of World: $230 million versus the three-analyst average estimate of $226.53 million. The reported number represents a year-over-year change of -3%.
  • Revenues- Europe: $347 million versus the three-analyst average estimate of $358.89 million. The reported number represents a year-over-year change of -2%.
  • Net sales- Connected Technology Solutions: $269 million compared to the $254.26 million average estimate based on five analysts.
  • Net sales- Wellspect Healthcare: $72 million versus the five-analyst average estimate of $75.87 million.
  • Net sales- Essential Dental Solutions: $369 million compared to the $345.49 million average estimate based on five analysts.
  • Net sales- Orthodontic and Implant Solutions: $241 million versus $261.83 million estimated by five analysts on average.
  • Adjusted Operating Income- Connected Technology Solutions: $16 million versus $17.68 million estimated by two analysts on average.
  • Adjusted Operating Income- Wellspect Healthcare: $26 million versus the two-analyst average estimate of $22.19 million.
  • Adjusted Operating Income- Orthodontic and Implant Solutions: $24 million versus the two-analyst average estimate of $40.81 million.
  • Adjusted Operating Income- Essential Dental Solutions: $132 million versus the two-analyst average estimate of $113.81 million.
View all Key Company Metrics for Dentsply here>>>

Shares of Dentsply have returned -2.2% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10